Chat with us, powered by LiveChat
  Pharmacy CE
ACPE Accredited Continuing Education for Pharmacists and Pharmacy Technicians

Updates in HIV Pharmacotherapy: It’s the beginning of a new era! – 1 CE

Activity Overview

A few new medications have been approved by the FDA in the last few years, causing new treatment regimens to be developed. A three-drug regimen was the cornerstone of HIV therapy. However, more recent data shows that two-drug regimens are equally effective in managing viral replication. This CE activity is aimed to update the audience about these changes. It recalls the different classes of HIV medications currently available, and discusses the preferred and alternative medication regimens based on the latest Department of Health and Human Services guidelines. Data from recently published research will be extensively reviewed.

Pharmacist Learning Objectives

At the conclusion of this continuing education activity, the participant will be able to:

  1. Recall the life cycle of HIV and where current treatment options target the virus
  2. Describe the different classes and regimens of highly active antiretroviral therapy (HAART)
  3. Identify the most appropriate time to initiate HAART, which medications to recommend first-line, and when to monitor and follow-up

          BUY NOW

Accreditation Statement

ACPEAchieveCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

AchieveCE is also accredited by the Florida Board of Pharmacy (provider no. 50-20641). This course is approved by CE Broker, with CE Broker No. 20-799031.

Faculty Information

Elif Özdener Poyraz, PharmD joined Fairleigh Dickinson University, School of Pharmacy & HealthSciences in August 2014. She primarily teaches pharmacotherapy and accompanying laboratory courses to students in their first, second, and third year of pharmacy school. She is also part of an interdisciplinary team in an outpatient community clinic providing clinical pharmacy services for underserved patients with HIV infection. She has no actual or potential conflicts of interest to disclose.

Financial Support Disclosure

This activity was developed by AchieveCE free of any commercial support.

Content Complexity

  Level 2. Basic Application of Skills and Concepts

Delivery Type

Home Study Monograph

}

Credits

1.0 Contact Hour

Category

AIDS Therapy

Target Audience

Pharmacist

Activity Type

Knowledge-based

Universal Activity Number

Pharmacist:
0657-0000-21-010-H02-P

Activity Release Date

April 30, 2021

Activity Expiration Date

April 30, 2024

Handout Download Link(s)

Already a Member?

Cost

$4.00

Requirements for Credit

Participants must score a passing grade of 70% or higher on the activity post-test and complete an activity evaluation. There are no time limits and unlimited test-taking attempts. Credits will be reported automatically to CPE Monitor and/or CE Broker if your license information is entered properly in your profile.

Hardware Requirements

Windows 8.1, Windows 10
Mac OS X 10.1 or higher
iOS 10+, Android 4.3+

Software Requirements

Google Chrome, Microsoft Edge, Mozilla Firefox
Adobe Acrobat Reader

Network Requirements

Broadband Internet Connection:
T1, Hi-speed DSL or Cable
4G cellular connection

Ready to Start?

          BUY NOW

You may also be interested in:

Direct Oral Anticoagulation Therapy Bleeding Risks and Emerging Reversal Agents Options – 2 CE

Each direct-acting oral anticoagulants agent has a unique pharmacokinetic profile and approved indication, therefore, educational initiatives are esse...

$8.00

Current Antibiotic Treatment Guidelines: A Guide for Pharmacy Professionals – 0.25 CE

With the rise in antibiotic-resistant bacteria, it is imperative that prescribers and pharmacy professionals practice good antibiotic stewardship to e...

$1.00

USP 800: Where Is It Bringing Us? How Sterile Are We Now? – 1 CE

Many new drugs have been added to the USP 800 hazardous drugs and unfortunately, many healthcare professionals have not been taught enough information...

$4.00